- Home
- CELC vs HURN Comparison
CELC vs HURN Comparison
Compare CELC & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- HURN
- Stock Information
- Founded
- CELC 2011
- HURN 2002
- Country
- CELC United States
- HURN United States
- Employees
- CELC N/A
- HURN N/A
- Industry
- CELC Medical Specialities
- HURN Professional Services
- Sector
- CELC Health Care
- HURN Consumer Discretionary
- Exchange
- CELC Nasdaq
- HURN Nasdaq
- Market Cap
- CELC 2.3B
- HURN 2.6B
- IPO Year
- CELC 2017
- HURN 2004
- Fundamental
- Price
- CELC $51.88
- HURN $147.96
- Analyst Decision
- CELC Strong Buy
- HURN Strong Buy
- Analyst Count
- CELC 5
- HURN 4
- Target Price
- CELC $67.20
- HURN $171.50
- AVG Volume (30 Days)
- CELC 1.1M
- HURN 149.4K
- Earning Date
- CELC 11-13-2025
- HURN 10-28-2025
- Dividend Yield
- CELC N/A
- HURN N/A
- EPS Growth
- CELC N/A
- HURN 37.96
- EPS
- CELC N/A
- HURN 5.74
- Revenue
- CELC N/A
- HURN $1,556,665,000.00
- Revenue This Year
- CELC N/A
- HURN $13.32
- Revenue Next Year
- CELC N/A
- HURN $8.31
- P/E Ratio
- CELC N/A
- HURN $25.65
- Revenue Growth
- CELC N/A
- HURN 9.24
- 52 Week Low
- CELC $7.58
- HURN $102.95
- 52 Week High
- CELC $63.06
- HURN $155.00
- Technical
- Relative Strength Index (RSI)
- CELC 53.91
- HURN 54.43
- Support Level
- CELC $45.15
- HURN $144.66
- Resistance Level
- CELC $50.00
- HURN $152.56
- Average True Range (ATR)
- CELC 3.48
- HURN 3.61
- MACD
- CELC -0.04
- HURN -0.45
- Stochastic Oscillator
- CELC 64.67
- HURN 38.35
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.